When it comes to biased benefits, there's plenty of blame to go around. But instead, the focus is increasingly on making things right.

Despite the political rollback of protections for the LGBTQ community, businesses' arms remain open and welcoming.

Benefits pros are breaking free of the traditional brokerage model, opting for broker-as-advisor businesses with innovative products and services.

Genetic-based therapies have the potential to prevent or cure previously deadly conditions. But they come with a hefty price tag.

The market for genetic matching and disease forecasting services has exploded. Are employers ready?

Employers are looking for innovators to help lower costs and improve outcomes. But which horse to back?

Politicians and Big Pharma find themselves in a tough spot as public pressure forces deeper digging into drug pricing policies.

Are loss-of-life-advocacy services the Next Big Thing in benefit plan design?